13 March 2014Asia-Pacific

Vaccine maker KAEL-GemVax appoints CPA Global as IP specialist

South Korean cancer vaccine maker KAEL-GemVax has appointed CPA Global as its IP management specialist.

Under the terms of the agreement, CPA Global will be responsible for renewing existing patents in the KAEL-GemVax IP portfolio, as well as patents that are currently under application in South Korea and overseas.

KAEL-GemVax makes pancreatic cancer vaccine TeloVac, which it acquired after buying Norwegian cancer vaccine company GemVax A/S in 2008.

IP team leader and patent lawyer at KAEL-GemVax, Lee Mi-hyun, said of the appointment: “Our IP is vitally important to the company’s future growth and development, so we needed a service provider who could ensure protection of our valuable intellectual assets around the world, while also delivering significant cost efficiencies in the management of our expanding IP portfolio.”

She added: “Working with CPA Global will help us develop a more comprehensive and competitive IP strategy.

“In addition to managing our renewals process, they will be able to assist us in identifying opportunities to optimise the value of our IP assets, both in Korea and internationally, through patent monetisation.”

Steve Kim, CPA Global’s director for Korea, said: “We are delighted to be working with KAEL-GemVax to help manage their valuable IP assets and to support the development and delivery of their global IP strategy.

“By appointing CPA Global to handle its renewals, the company is able to free up its in-house IP team to focus on more strategic work, such as developing additional revenue streams from its prized IP assets.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk